文献速递术前评估与围术期医学区域麻醉与超声

FDA警告后医院从羟乙基淀粉换用白蛋白对肌肉骨骼手术出血的影响

Bleeding After Musculoskeletal Surgery in Hospitals That Switched From Hydroxyethyl Starch to Albumin Following a Food and Drug Administration Warning.
PubMed 文献 · Anesth Analg · 2020-01-01

该研究基于Premier数据库,回顾性分析2013年FDA黑框警告前后一年内肌肉骨骼手术患者。在23家胶体使用从HES转向白蛋白的「转换型」医院中,警告后大出血发生率未显著下降(斜率比0.98,95%CI 0.93-1.04;DID比值比0.93,95%CI 0.46-1.86)。

要点

  • FDA警告后转换型医院白蛋白使用比例从13.3%升至75.9%。
  • 转换型医院大出血率警告前14.9%,警告后12.6%,无显著差异。
  • 以非转换型医院为对照的DID分析显示无显著差异。

核心结论

  • 在转换型医院中,FDA警告后肌肉骨骼手术患者围术期大出血率无显著下降,可能因实践改变不完全。

研究设计与样本

  • 回顾性、准实验、重复横断面、中断时间序列研究,使用Premier Healthcare Database。
  • 纳入23家转换型医院和279家非转换型医院,分析FDA警告前后各12个月肌肉骨骼手术患者。
  • 转换型医院共3078例患者(警告前1892例,警告后1186例)。

主要发现

  • 转换型医院大出血率警告前282/1892(14.9%),警告后149/1186(12.6%)。
  • 分段回归调整后斜率比为0.98(95%CI 0.93-1.04)。
  • DID比值比为0.93(95%CI 0.46-1.86),无显著差异。

临床怎么用

  • 对于肌肉骨骼手术患者,从HES转向白蛋白的机构层面改变未显著降低围术期大出血率。
  • 提示需关注实践改变完整性对患者结局的影响。

局限性

  • 研究为回顾性观察性设计,可能存在残余混杂。
  • 转换型医院数量较少(23家),实践改变可能不完全。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While US Food and Drug Administration (FDA) black box warnings are common, their impact on perioperative outcomes is unclear. Hydroxyethyl starch (HES) is associated with increased bleeding and kidney injury in patients with sepsis, leading to an FDA black box warning in 2013. Among patients undergoing musculoskeletal surgery in a subset of hospitals where colloid use changed from HES to albumin following the FDA warning, we examined the rate of major perioperative bleeding post- versus pre-FDA warning. METHODS: The authors of this article used a retrospective, quasi-experimental, repeated cross-sectional, interrupted time series study of patients undergoing musculoskeletal surgery in hospitals within the Premier Healthcare Database, in the year before and year after the 2013 FDA black box warning. We examined patients in 23 "switcher" hospitals (where the percentage of colloid recipients receiving HES exceeded 50% before the FDA warning and decreased by at least 25% in absolute terms after the FDA warning) and patients in 279 "nonswitcher" hospitals. Among patients having surgery in "switcher" and "nonswitcher" hospitals, we determined monthly rates of major perioperative bleeding during the 12 months after the FDA warning, compared to 12 months before the FDA warning. Among patients who received surgery in "switcher" hospitals, we conducted a propensity-weighted segmented regression analysis assessing differences-in-differences (DID), using patients in "nonswitcher" hospitals as a control group. RESULTS: Among 3078 patients treated at "switcher" hospitals (1892 patients treated pre-FDA warning versus 1186 patients treated post-FDA warning), demographic and clinical characteristics were well-balanced. Two hundred fifty-one (13.3%) received albumin pre-FDA warning, and 900 (75.9%) received albumin post-FDA warning. Among patients undergoing surgery in "switcher" hospitals during the pre-FDA warning period, 282 of 1892 (14.9%) experienced major bleeding during the hospitalization, compared to 149 of 1186 (12.6%) following the warning. In segmented regression, the adjusted ratio of slopes for major perioperative bleeding post- versus pre-FDA warning was 0.98 (95% confidence interval [CI], 0.93-1.04). In the DID estimate using "nonswitcher" hospitals as a control group, the ratio of ratios was 0.93 (95% CI, 0.46-1.86), indicating no significant difference. CONCLUSIONS: We identified a subset of hospitals where colloid use for musculoskeletal surgery changed following a 2013 FDA black box warning regarding HES use in sepsis. Among patients undergoing musculoskeletal surgery at these "switcher" hospitals, there was no significant decrease in the rate of major perioperative bleeding following the warning, possibly due to incomplete practice change. Evaluation of the impact of systemic changes in health care may contribute to the understanding of patient outcomes in perioperative medicine.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Krishnamoorthy V, Ellis AR, McLean DJ, et al. Bleeding After Musculoskeletal Surgery in Hospitals That Switched From Hydroxyethyl Starch to Albumin Following a Food and Drug Administration Warning. Anesth Analg. 2020. PMID: 32925340. doi:10.1213/ANE.0000000000004942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。